Second Amendment to Warrant Certificate
This Second Amendment to Warrant Certificate, dated as of May 12, 2025 (this “Amendment”), is entered into by and among Biodesix, Inc. a Delaware corporation (the “Company”) and Perceptive Credit Holdings IV, LP, a Delaware limited partnership (the “Holder”).
Recitals
Whereas, the Company issued to the Holder that certain Warrant Certificate, dated as of November 21, 2022, as amended by that certain First Amendment to Warrant Certificate, dated February 28, 2025, and this Amendment (the “Warrant”). Capitalized terms used herein but not otherwise defined herein shall have the meanings ascribed thereto in the Warrant.
Whereas, following that certain Fifth Amendment to Credit Agreement and Guaranty, dated as of February 28, 2025, by and among the Company, as borrower, the lenders party thereto, and Holder, as administrative agent for the lenders, the Company and the Holder have agreed to amend certain provisions of the Warrant.
Whereas, the Company and the Holder are willing to make such amendments to the Warrant as are further described herein, in accordance with and subject to the terms and conditions of this Amendment.
Now, Therefore, in consideration of the premises and the mutual covenants and the agreements herein set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows:
1.1Section 2(a)(i) of the Warrant is hereby amended to state in its entirety to read as follows:
(i) On the date hereof (the “Initial Vesting Date”), 3,000,000 Warrant Shares shall become vested and exercisable (such Warrant Shares, the “Initial Warrant Shares”) and shall be exercisable at an Exercise Price equal to $0.4191 (the “Initial Warrant Exercise Price”).
1.2Section 2(a)(ii) of the Warrant is hereby amended to state in its entirety to read as follows:
(ii) On the Tranche B Loan Borrowing Date (as defined in the Credit Agreement) (the “Second Tranche Vesting Date”), an additional 1,000,000 Warrant Shares shall become vested and exercisable (such Warrant Shares, the “Second Tranche Warrant Shares”) and shall be exercisable at an Exercise Price equal to $0.4191 (the “Second Tranche Exercise Price”).
1.3Section 2(a)(iii) of the Warrant is hereby amended to state in its entirety to read as follows:
(iii) On the Tranche C Loan Borrowing Date (as defined in the Credit Agreement) (the “Third Tranche Vesting Date”), an additional 1,000,000 Warrant Shares shall become vested and exercisable (such Warrant Shares, the “Third Tranche Warrant Shares”) and shall be exercisable at an Exercise Price equal to $0.4191 (the “Third Tranche Exercise Price”).
2Effect of Amendment. On and after the date hereof, each reference in the Warrant to “this Warrant”, “hereunder”, “hereof”, “herein” or words of like import referring to the Warrant, shall mean and be a reference to the Warrant after giving effect to this Amendment. Except as specifically set forth in this Amendment, the Warrant remains in full force and effect and is hereby ratified and confirmed.
3Governing Law. This Amendment, and all questions concerning the construction, validity, enforcement and interpretation of the Amendment, shall be governed by and construed and enforced in accordance with the internal laws of the State of New York.
4Counterparts. This Amendment may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same Amendment. Delivery of an executed counterpart of this Amendment by facsimile, DocuSign or a scanned copy by electronic mail shall be equally as effective as delivery of an original executed counterpart of this Amendment.
5Binding Effect. This Amendment will be binding upon and inure to the benefit of and is enforceable by the respective successors and permitted assigns of the parties hereto.
6Incorporation By Reference. The provisions set forth in Sections 23 (Submission to Jurisdiction) and 24 (Waiver of Jury Trial) of the Warrant shall apply to this Amendment in all respects.
[Remainder of page intentionally left blank; signatures on following pages]
IN WITNESS WHEREOF, the Company and Holder have duly executed this Amendment as of the date first written above.
COMPANY: BIODESIX, INC., a Delaware corporation
|
|
|
Date: May 13, 2025 |
By: |
/s/ Robin Harper Cowie |
|
|
Robin Harper Cowie |
|
|
Chief Financial Officer |
HOLDER: PERCEPTIVE CREDIT HOLDINGS IV, LP,
a Delaware limited partnership
By: Perceptive Credit Opportunities GP, LLC, its general partner
|
|
|
Date: May 13, 2025 |
By: |
/s/ Sandeep Dixit |
|
|
Sandeep Dixit |
|
|
Chief Credit Officer |
|
|
|
Date: May 13, 2025 |
By: |
/s/ Sam Chawla |
|
|
Sam Chawla |
|
|
Portfolio Manager |